AntriaBio licenses portfolio of enzymes to treat vision loss in adults

Facebook Twitter Google+ LinkedIn Email PrintLOUISVILLE — AntriaBio Inc. (OTC: ANTB) is licensing from ActiveSite Pharmaceuticals. AntriaBio is licensing ActiveSite’s oral plasma kallikrein inhibitor portfolio, which will be used in human and animal health, according to a news release. The portfolio will be used for targeting the treatment of diabetic macular edema and other plasma kallikrein-mediated diseases.  Diabetic macular edema is the primary cause of vision loss in working-age adults globally. About 750,000 people in…